TriNetX bolsters clinical research network with Custodix buy, quadruples European staff

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/carloscastilla)
(Image: Getty/carloscastilla)

Related tags: TriNetX, Clinical research, Data

TriNetX acquires Belgium-based Custodix NV to support industry partners looking to collaborate with non-US hospitals – becoming a “one-stop-shop” for clinical data, says SVP.

The global health research network TriNetX today announced its acquisition of Belgium-based Custodix NV and its InSite network, which operate in 12 countries throughout Europe.

Custodix NV provides clinical trial design, patient feasibility and recruitment services. The company’s InSite platform was developed as part of the Innovative Medicines Initiative (IMI​) research program in collaboration with the pharmaceutical industry through the EHR4CR​ project.

As per the acquisition – financial details of which were not disclosed – Custodix becomes a division ofTriNetX and will under the name InSite, aTriNetX company. The deal quadruples the size of TriNetX's current European staff and establishes an EU headquarters in Belgium.

Additionally, Custodix CEO Brecht Claerhout will now serve as senior vice president and managing director of InSite and Europe. 

“Our industry partners are conducting research on a global scale and looking to collaborate with non-US hospitals. Given TriNetX’s momentum, we felt the fastest way to create a ‘one-stop shop’ for clinical data, was to unite with the leading European research network, InSite,” ​said TriNetX​ SVP of Corporate Development Maulik Mehta.

“This lead to our acquisition of Custodix NV,”​ he told us. “For Custodix, they wanted to be able to offer their hospital community more clinical trials and together we look forward to rolling out new functionality across the networks.”

As for how the companies will be integrated, Mehta said the vision is to create “one experience”​ for its customers.

“We are working quickly to integrate the two networks on to a single self-service platform. In the short term, InSite’s hospital community can expect more clinical trials and in the medium term, access to more functionality,”​ he explained. “Throughout this, InSite remains the local European research network and the values, company contacts and offerings remain unchanged.”

TriNetX last month closed a Series D financing round​, bringing total funding to $102m as the network continues to expand globally. The company’s customer base currently includes 29 industry partners, including Novartis, Sanofi​ and Pfizer​, and the contract research organizations (CROs) Syneos and Icon​.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more